Seminars in nephrology最新文献_第3页

Systemic Amyloidosis and Kidney Transplantation: An Update 系统性淀粉样变性与肾移植：最新进展。

IF 2.8 3区医学

Seminars in nephrology Pub Date : 2024-01-01 DOI: 10.1016/j.semnephrol.2024.151496

Shankara K. Anand MS , Vaishali Sanchorawala MD , Ashish Verma MBBS

引用次数: 0

Epidemiology of Cancer in Kidney Transplant Recipients 肾移植受者的癌症流行病学。

IF 2.8 3区医学

Seminars in nephrology Pub Date : 2024-01-01 DOI: 10.1016/j.semnephrol.2024.151494

David Massicotte-Azarniouch MD, MSc , J. Ariana Noel MD, MSc , Greg A. Knoll MD, MSc

{"title":"Epidemiology of Cancer in Kidney Transplant Recipients","authors":"David Massicotte-Azarniouch MD, MSc , J. Ariana Noel MD, MSc , Greg A. Knoll MD, MSc","doi":"10.1016/j.semnephrol.2024.151494","DOIUrl":"10.1016/j.semnephrol.2024.151494","url":null,"abstract":"<div><p>Kidney transplantation is the ideal treatment modality for patients with end-stage kidney disease, with excellent outcomes post-transplant compared with dialysis. However, kidney transplant recipients are at increased risk of infections and cancer because of the need for immunosuppression. Kidney transplant recipients have approximately two to three times greater risk of developing cancer than the general population, and cancer is a major contributor to morbidity and mortality. Most of the increased risk is driven by viral-mediated cancers such as post-transplant lymphoproliferative disorder, anogenital cancers, and Kaposi sarcoma. Nonmelanoma skin cancer is the most frequent type of cancer in kidney transplant recipients, likely due to an interaction between ultraviolet radiation exposure and decreased immune surveillance. Occurrence of the more common types of solid organ cancers seen in the general population, such as breast, prostate, lung, and colorectal cancers, is not, or is only mildly, increased post-transplant. Clinical care and future research should focus on prevention and on improving outcomes for important immunosuppression-related malignancies, and treatment options for other cancers occurring in the transplant setting.</p></div>","PeriodicalId":21756,"journal":{"name":"Seminars in nephrology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0270929524000111/pdfft?md5=99b92dccff332e7ea4e7c242ea388063&pid=1-s2.0-S0270929524000111-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140306845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Premalignant Lesions in the Kidney Transplant Candidate 肾移植候选者的恶性前病变

IF 2.8 3区医学

Seminars in nephrology Pub Date : 2024-01-01 DOI: 10.1016/j.semnephrol.2024.151495

Paul M. Schroder MD, PhD, Ben E. Biesterveld MD, David P. Al-Adra MD, PhD

引用次数: 0

Post-Transplant Lymphoproliferative Disorders 移植后淋巴细胞增生性疾病（肾脏病研讨会综述）。

IF 2.8 3区医学

Seminars in nephrology Pub Date : 2024-01-01 DOI: 10.1016/j.semnephrol.2024.151503

Vikas R. Dharnidharka MD, MPH , Marianna B. Ruzinova MD, PhD , Lianna J. Marks MD

引用次数: 0

Patient-Centered Research and Outcomes in Cancer and Kidney Transplantation 以患者为中心的癌症和肾移植研究与成果。

IF 2.8 3区医学

Seminars in nephrology Pub Date : 2024-01-01 DOI: 10.1016/j.semnephrol.2024.151499

Ellen Dobrijevic MD , Nicole Scholes-Robertson PhD , Chandana Guha MA , Martin Howell PhD , Allison Jauré PhD , Germaine Wong MD, PhD , Anita van Zwieten PhD

引用次数: 0

Introduction: Clinical Innovations in Transplant Onconephrology 简介：移植肿瘤肾脏病学的临床创新。

IF 2.8 3区医学

Seminars in nephrology Pub Date : 2024-01-01 DOI: 10.1016/j.semnephrol.2024.151493

Naoka Murakami MD, PhD, Germaine Wong MD, PhD

引用次数: 0

Access to Cancer Care: Prevention and Screening for Females Post Kidney Transplantation Around the World 获得癌症护理：世界各地肾移植后女性的预防和筛查。

IF 2.8 3区医学

Seminars in nephrology Pub Date : 2024-01-01 DOI: 10.1016/j.semnephrol.2024.151502

Nicole Scholes-Robertson PhD , Zibya Barday PhD , Bianca Davidson MBChB , Abirami Krishnan MBBS, MD, MRCP , Maleeka Ladhani MBBS, PhD , Louise Lerminiaux BBus, MBA , Ruth Sapir-Pichhadze MD, MSc, PhD , Amanda Vinson MD, MSc

{"title":"Access to Cancer Care: Prevention and Screening for Females Post Kidney Transplantation Around the World","authors":"Nicole Scholes-Robertson PhD , Zibya Barday PhD , Bianca Davidson MBChB , Abirami Krishnan MBBS, MD, MRCP , Maleeka Ladhani MBBS, PhD , Louise Lerminiaux BBus, MBA , Ruth Sapir-Pichhadze MD, MSc, PhD , Amanda Vinson MD, MSc","doi":"10.1016/j.semnephrol.2024.151502","DOIUrl":"10.1016/j.semnephrol.2024.151502","url":null,"abstract":"<div><p>Kidney transplantation offers recipients superior outcomes and improved quality of life compared with dialysis. However, the need for ongoing immunosuppression places recipients at increased risk of certain forms of cancer. Screening and early detection of precancerous lesions are one of the few proven ways to lower the risk of cancer morbidity and mortality in the transplant population. Women have additional barriers to cancer screening services globally, especially in low- and middle-income countries as well as within certain disadvantaged groups in high-income countries. There is a dearth of published data on screening guidelines and policies on post-transplant malignancy in female recipients. It is vital that health care providers and patients are educated regarding the risks of cancer at all post-transplant stages and that the recommended screening policies are adhered to in order to reduce associated morbidity and mortality in this at-risk group.</p></div>","PeriodicalId":21756,"journal":{"name":"Seminars in nephrology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141293687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Kidney Transplantation in Multiple Myeloma and Monoclonal Gammopathy of Renal Significance 多发性骨髓瘤和单克隆肾病的肾移植。

IF 2.8 3区医学

Seminars in nephrology Pub Date : 2024-01-01 DOI: 10.1016/j.semnephrol.2024.151497

Nelson Leung MD , Cihan Heybeli MD

{"title":"Kidney Transplantation in Multiple Myeloma and Monoclonal Gammopathy of Renal Significance","authors":"Nelson Leung MD , Cihan Heybeli MD","doi":"10.1016/j.semnephrol.2024.151497","DOIUrl":"10.1016/j.semnephrol.2024.151497","url":null,"abstract":"<div><p>Recent advances in the treatment of plasma cell disorders (PCDs) have provided a wealth of therapy alternatives and improved overall survival tremendously. Various types of PCDs are associated with kidney injury and end-stage kidney disease in a considerable number of patients. Kidney transplantation (KTx) is the best option for renal replacement therapy in select patients in terms of both quality of life parameters and overall survival. Even with modern therapies, all PCDs carry the risk of hematologic progression, whereas histologic recurrence and graft loss are other prevailing concerns in these patients. The risk of mortality is also higher in some of these disorders compared with KTx recipients who suffer from other causes of kidney disease. Unlike solid cancers, there is no well-defined “waiting time” after hematologic remission before proceeding to KTx. Thus, clinicians are usually reluctant to recommend KTx to patients who develop end-stage kidney disease due to PCDs. This review aims to provide the current evidence on KTx outcomes in patients with monoclonal gammopathy of renal significance and multiple myeloma. Although immunoglobulin light chain amyloidosis is a monoclonal gammopathy of renal significance subtype, KTx outcomes in this group are mentioned in another chapter of this issue.</p></div>","PeriodicalId":21756,"journal":{"name":"Seminars in nephrology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140132467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immune Checkpoint Inhibitors in Recipients of Renal Allografts 免疫检查点抑制剂在肾移植受者中的应用

IF 2.8 3区医学

Seminars in nephrology Pub Date : 2024-01-01 DOI: 10.1016/j.semnephrol.2024.151500

Karthik Venkataraman MBBS , Tania Salehi MBBS , Robert P. Carroll MD, PhD, FRACP, A(ACHI)

引用次数: 0

Adoptive Immune Effector Cell Therapies in Cancer and Solid Organ Transplantation: A Review 癌症和实体器官移植中的适应性免疫效应细胞疗法：综述。

IF 2.8 3区医学

Seminars in nephrology Pub Date : 2024-01-01 DOI: 10.1016/j.semnephrol.2024.151498

Brittany Schreiber MD , Sudipta Tripathi PhD , Sarah Nikiforow MD, PhD , Anil Chandraker MBChB

{"title":"Adoptive Immune Effector Cell Therapies in Cancer and Solid Organ Transplantation: A Review","authors":"Brittany Schreiber MD , Sudipta Tripathi PhD , Sarah Nikiforow MD, PhD , Anil Chandraker MBChB","doi":"10.1016/j.semnephrol.2024.151498","DOIUrl":"10.1016/j.semnephrol.2024.151498","url":null,"abstract":"<div><p>Cancer is one of the most devastating complications of kidney transplantation and constitutes one of the leading causes of morbidity and mortality among solid organ transplantation (SOT) recipients. Immunosuppression, although effective in preventing allograft rejection, inherently inhibits immune surveillance against oncogenic viral infections and malignancy. Adoptive cell therapy, particularly immune effector cell therapy, has long been a modality of interest in both cancer and transplantation, though has only recently stepped into the spotlight with the development of virus-specific T-cell therapy and chimeric antigen receptor T-cell therapy. Although these modalities are best described in hematopoietic cell transplantation and hematologic malignancies, their potential application in the SOT setting may hold tremendous promise for those with limited therapeutic options. In this review, we provide a brief overview of the development of adoptive cell therapies with a focus on virus-specific T-cell therapy and chimeric antigen receptor T-cell therapy. We also describe the current experience of these therapies in the SOT setting as well as the challenges in their application and future directions in their development.</p></div>","PeriodicalId":21756,"journal":{"name":"Seminars in nephrology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140330108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0